DT-PACE regimen
WikiDoc Resources for DT-PACE regimen |
Articles |
---|
Most recent articles on DT-PACE regimen Most cited articles on DT-PACE regimen |
Media |
Powerpoint slides on DT-PACE regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on DT-PACE regimen at Clinical Trials.gov Trial results on DT-PACE regimen Clinical Trials on DT-PACE regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on DT-PACE regimen NICE Guidance on DT-PACE regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on DT-PACE regimen Discussion groups on DT-PACE regimen Patient Handouts on DT-PACE regimen Directions to Hospitals Treating DT-PACE regimen Risk calculators and risk factors for DT-PACE regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for DT-PACE regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Dexamethasone-Thalidomide-Platinol-Adriamycin-Cytoxan-Etoposide Regimen; DT-PACE Regimen
Overview
DT-PACE regimen refers to a regimen consisting of dexamethasone, thalidomide (DT) and cisplatin, doxorubicin, cyclophosphamide and etoposide (PACE) used for the treatment of relapsed and refractory multiple myeloma.[1]
Regimen
DDexamethasone
TThalidomide
PCisplatin
ADoxorubicin (Adriamycin)
CCyclophosphamide
EEtoposide
Indications
- Relapsed and refractory multiple myeloma[2]